Assuming time is required, the following results were found.

  • #ECTRIMS2019 - Longer DMT Use and Female Sex Seen to Protect Against SPMS Conversion - Multiple Sclerosis News Today

    in RRMS to a more steadily worsening phase characterized by nerve damage or loss, and the accumulation of disability over time. Before DMTs became available, studies indicated that nearly all (about 90%) of those with RRMS would transition to SPMS...

    https://mschristian.org/index.php/blog/ectrims2019-longer-dmt-use-and-female-sex-seen-to-protect-against-spms-conversion-multiple-sclerosis-news-today
  • Siponimod Delays Time to Wheelchair in Secondary Progressive MS - Neurology Times

    (MS) beyond the study’s core findings. The oral selective sphingosine-1-phosphate receptor modulator significantly delayed time to wheelchair dependence.1 The data were presented by Patrick Vermersch, MD, PhD, vice-dean, faculty of medicine, University...

    https://mschristian.org/index.php/blog/siponimod-delays-time-to-wheelchair-in-secondary-progressive-ms-neurology-times
  • Pregnancy & MS - Considerations before starting a family

    T. Social Worker When I was diagnosed with multiple sclerosis (MS), I was 26 years old and newly married. I was working full time and had just started graduate school. I remember wondering early on in my diagnosis if I would ever be able to have a...

    https://mschristian.org/index.php/blog/pregnancy-ms-considerations-before-starting-a-family
  • MS & Socializing: A Few Things to Remember

    I struggle in this area as well, however, I do have some tips to help improve your chances of experiencing that crucial time with other human beings. Remember it’s important You’ve probably heard the phrase “humans are social creatures” a number of...

    https://mschristian.org/index.php/blog/ms-socializing-a-few-things-to-remember
  • 'Mom, I ran the race for you': Laurel runner dedicates win to ailing mother - KTVQ Billings News

    with Multiple Sclerosis, a disabling disease of the central nervous system. The Eastern A divisional meet was the first time in a month that Adriana was able to see Andria run, and Andria won her first cross country race of her career. “I was super...

    https://mschristian.org/index.php/blog/mom-i-ran-the-race-for-you-laurel-runner-dedicates-win-to-ailing-mother-ktvq-billings-news
  • What to know about secondary progressive multiple sclerosis (SPMS)

    stage of multiple sclerosis. Instead of having symptom relapses and remissions, a person's symptoms steadily get worse over time. Most people, but not everyone, with relapsing-remitting multiple sclerosis (RRMS) will eventually develop secondary...

    https://mschristian.org/index.php/blog/what-to-know-about-secondary-progressive-multiple-sclerosis-spms-1
  • What to know about optic neuritis and MS

    in the optic nerve. This damage is called optic neuritis. Although the symptoms of optic neuritis tend to subside over time, some people may also benefit from various treatments. Visual disturbances are among the most common symptom that people with MS...

    https://mschristian.org/index.php/blog/what-to-know-about-optic-neuritis-and-ms
  • New app offers faster and easier assessment for multiple sclerosis

    paper-based assessment tool, researchers say they found that the app produced highly accurate results while reducing test time from about 23 to 14 minutes. Study results are described in the July 2019 online issue of the International Journal of MS...

    https://mschristian.org/index.php/blog/new-app-offers-faster-and-easier-assessment-for-multiple-sclerosis
  • Aubagio (teriflunomide)

    (breaks down) Aubagio and many other drugs in a similar way. When medications are broken down together, they can sometimes interact with each other. Aubagio can cause your body to break down some drugs quickly or slowly. This can increase or decrease...

    https://mschristian.org/index.php/blog/aubagio-teriflunomide
  • Economic Factors Amplify Burden of Disease for Patients With Multiple Sclerosis

    life, loss of work, and anxiety about the future." Economic factors may include loss of income for the patient, care-giving time for the family, and societal costs, which include burden on the healthcare system due to high healthcare utilization. Not...

    https://mschristian.org/index.php/blog/economic-factors-amplify-burden-of-disease-for-patients-with-multiple-sclerosis
  • Tecfidera (dimethyl fumarate)

    If your lymphocyte levels become too low, your doctor may suggest that you stop taking Tecfidera for a set amount of time, or permanently. Liver effects Tecfidera can cause liver side effects. It may increase levels of certain liver enzymes that are...

    https://mschristian.org/index.php/blog/tecfidera-dimethyl-fumarate
  • MS Is Making Me Lose My Grip - Everyday Health

    can be a consequence of weakness, numbness, or lack of coordination brought on by MS. Andy Baker/Getty Images How many times hasn’t a glass, a toothbrush, a pencil, or innumerable other objects jumped from my multiple sclerosis (MS)–affected hands when...

    https://mschristian.org/index.php/blog/ms-is-making-me-lose-my-grip-everyday-health
  • DOUBT Study Clarifies Role of MRI for TIA or Stroke

    no history of a similar prior event (OR 1.87, 95% CI 1.12-3.11), and abnormal results of neurologic examination at time of evaluation (OR 1.71, 95% CI 1.11-2.65) were all associated with a higher risk of DWI positivity. A total of seven patients (0.7%)...

    https://mschristian.org/index.php/blog/doubt-study-clarifies-role-of-mri-for-tia-or-stroke
  • Vision Quest - The New York Times

    the last thing he said before we left the small, windowless exam room. He said: “I will see you in two weeks, but in the meantime, please call me if the bottom drops out.” What would that be? Total blindness? Worse? As it happened, I’d been preparing my...

    https://mschristian.org/index.php/blog/vision-quest-the-new-york-times
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    CDP (26% versus placebo, p=0.0058) [2]. In the subgroup of Mayzent-treated patients with active disease, results showed: Time to onset of three‑month and six‑month CDP was significantly delayed by 31% compared to placebo and by 37% compared to placebo,...

    https://mschristian.org/index.php/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • #ECTRIMS2019 - Mayzent's Benefits for MS Patients a 'Key Question,' Says EXPAND's Principal Investigator - Multiple Sclerosis News Today

    said Kappos, referring to the new findings shared at the conference. Results also suggested that Mayzent can delay the time to wheelchair dependence by approximately 4.3 years, compared with placebo. These estimates were based on a data extrapolation...

    https://mschristian.org/index.php/blog/ectrims2019-mayzent-s-benefits-for-ms-patients-a-key-question-says-expand-s-principal-investigator-multiple-sclerosis-news-today
  • Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2 - Science

    sequencing (RNA-seq) and reverse transcription polymerase chain reaction (RT-PCR), were substantially elevated over multiple time points at similar magnitudes to recognized type I interferonopathies (Fig. 1, B and C), notably without evidence of...

    https://mschristian.org/index.php/blog/severe-type-i-interferonopathy-and-unrestrained-interferon-signaling-due-to-a-homozygous-germline-mutation-in-stat2-science
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary endpoints of delaying time to confirmed disability progression were also met[1]; additional secondary endpoints will be presented at ECTRIMS Ofatumumab, a...

    https://mschristian.org/index.php/blog/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies-1
  • 5 Ways to Have a Better MRI Experience With MS

    (MRI) scans are commonly performed to establish a diagnosis of multiple sclerosis (MS) and to monitor its progression over time. MRIs use strong magnets and radio waves to create images of internal structures of the body. An MRI scan of your brain and...

    https://mschristian.org/index.php/blog/5-ways-to-have-a-better-mri-experience-with-ms
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    rate over Aubagio®*(teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary endpoints of delaying time to confirmed disability progression were also met[1]; additional secondary endpoints will be presented at ECTRIMS #Ofatumumab, a...

    https://mschristian.org/index.php/blog/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies

Results 1 - 20 of 123
 
 

Follow Us on Twitter

Follow Us On Twitter - Image